Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Emergent BioSolutions Expands Biodefense Franchise

by Global Biodefense Staff
December 17, 2014
Gram Negative Burkholderia pseudomallei

Gram-negative Burkholderia pseudomallei bacteria, which was grown on a medium of sheep’s blood agar for 72 hours. Background image credit: Dr. Todd Parker/CDC

Emergent BioSolutions today announced that it has acquired the lead broad-spectrum antibiotic candidate, currently receiving Defense Threat Reduction Agency (DTRA) development funding, from Evolva Holding SA.

The oral and IV treatment for Burkholderia pseudomallei as well as other bioterror agents is EV-035, a series of novel small molecule broad spectrum antibiotics of the 4-oxoquinolizine class and targets bacterial type IIa topoisomerase.

The lead molecule in the series, GC-072, has demonstrated protection in vivo from lethal B. pseudomallei infection when administered orally. GC-072 is being developed as a potential oral and IV treatment for B. pseudomallei under a three-year, $15 million contract with DTRA.

B. pseudomallei is a gram-negative pathogen classified by the Centers for Disease Control and Prevention as a Category B bioterrorism agent and a priority threat capable of being easily weaponized and disseminated.

“Emergent’s acquisition of the EV-035 series of broad spectrum antibiotics further aligns us with the U.S. government’s strategic objective of combating antibiotic-resistant bacteria, which the Administration considers a national security priority that requires continued development funding,” said Adam Havey, executive vice president and president, biodefense division of Emergent BioSolutions.

In vitro models have shown activity of the EV-035 series of molecules in gram-negative and gram-positive bacteria, including multi-drug resistant and quinolone-resistant bacteria (e.g., Escherichia coli, Acinetobacter baumannii, Staphylococcus aureus [including methicillin-resistant S. aureus or MRSA], Streptococcus pneumoniae, Enterococcus faecalis, Pseudomonas aeruginosa, and Haemophilus influenzae) and biodefense pathogens (e.g., Burkholderia pseudomallei, Bacillus anthracis, Francisella Tularensis, and Yersinia pestis).

The scope of the DTRA contract includes investigating GC-072 as a treatment for B. pseudomallei in preclinical in vitro and in vivo studies, conducting formulation, manufacturing and toxicology studies, exploring efficacy in additional multi-drug resistant biodefense and commercial pathogens, and preparing an Investigational New Drug application for submission to the U.S. Food and Drug Administration.

Tags: AntimicrobialsBioterrorismBurkholderiaDefense Threat Reduction AgencyF. tularensis

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC